RecruitingPhase 1NCT07275242

A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor

An Open-Label, Multi-site Phase I Clinical Study of SHR-A1811(sc) Subcutaneous Injection: Evaluating Pharmacokinetics, Safety, Tolerability, and Efficacy in Patients With Solid Tumor

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrollment

107 participants

Start Date

Dec 23, 2025

Study Type

INTERVENTIONAL

Conditions

Solid Tumor

Summary

The study is being conducted to evaluate the pharmacokinetics , safety, tolerability and efficacy in patients with solid tumor.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called SHR-A1811 Subcutaneous Injection and a drug called SHR-A1811 for Injection for people with solid tumor. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.